Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.88AUD
24 Jul 2017
Change (% chg)

$-0.06 (-3.35%)
Prev Close
$1.94
Open
$1.93
Day's High
$1.94
Day's Low
$1.85
Volume
696,331
Avg. Vol
969,281
52-wk High
$3.44
52-wk Low
$1.07

Select another date:

Mon, Jul 10 2017

BRIEF-Mesoblast Ltd files ‍​for $180 million American depositary shares representing ordinary shares

* Mesoblast Ltd - files ‍​for $180 million American depositary shares representing ordinary shares Source text: (http://bit.ly/2u50ziE) Further company coverage:

UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

May 25 Australian regenerative medicine maker Mesoblast Ltd on Thursday posted a narrower quarterly loss but booked a rise in research and development costs.

CORRECTED-Australia's Mesoblast flags "going concern" doubts

May 25 Australian regenerative medicine maker Mesoblast Ltd said on Thursday it needed new funding from a third party partner or from capital raising to continue in business as it had cash reserves of $69.1 million.

BRIEF-Mesoblast receives A$3.7m from Australian Government for research and development

* Asx alert-Mesoblast receives A$3.7m from AUS Government for research and development-MSB.AX Source text for Eikon: Further company coverage:

BRIEF-FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy

* FDA clears heart disease trial at Harvard's Boston Children's Hospital using Mesoblast's Cell Therapy to grow heart muscle in children with congenital heart disease Source text for Eikon: Further company coverage:

BRIEF-IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial

* Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial

BRIEF-Mesoblast updates on durable three year outcomes in disc disease

* Mesoblast says 36-month results from randomized, placebo-controlled 100- patient phase 2 trial of allogeneic mpcs in patients with chronic low back pain

BRIEF-FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

* FDA grants fast track designation for Mesoblast's cell therapy in children with acute graft versus host disease

BRIEF-Mesoblast provides data from mid-stage trial on cell therapy MPC-300-IV

* Announced 39-week data from phase 2 trial in patients with rheumatoid arthritis resistant to anti-tumor necrosis factor agents

Select another date: